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Abstract
Recent studies on traditional medicine (TM) have begun to change perspectives on TM effects and its role in the
health of various populations. The safety and effectiveness of some TMs have been studied, paving the way to
better collaboration between modern and traditional systems. Traditional medicines still remain a largely untapped
health resource: they are not only sources of new leads for drug discoveries, but can also provide lessons and
novel approaches that may have direct public-health and economic impact. To optimize such impact, several
interventions have been suggested, including recognition of TM’s economic and medical worth at academic and
health policy levels; establishing working relationships with those prescribing TM; providing evidence for safety and
effectiveness of local TM through appropriate studies with malaria patients; spreading results for clinical
recommendations and health policy development; implementing and evaluating results of new health policies that
officially integrate TM.
Why focus on traditional medicine as
complementary or alternative solutions in malaria
control programmes?
The aim of this paper is to discuss past, present and espe-
cially future contributions of Traditional medicine (TM) to
malaria control programmes. In rural areas in Africa and
elsewhere in developing countries, traditional medicines
are often trusted, affordable and accessible, as they are
made from locally available plants or other elements [1].
A large proportion of the population continues to rely on
traditional medicine practitioners and local medicinal
plants for primary health care, as a choice or when there is
no access to other medicine [1-3].
This reflexion article is an attempt to show trends in TM
research and practice in order to answer the following ques-
tion: should TM be officially considered and recommended
as complementary or alternative solutions in malaria con-
trol programmes? And, if so, under what conditions?
The usual reason for interest in TM stems from the
recognition that two of the major anti-malarial drugs,
quinine and artemisinin trace their origin to traditional
medicine [4-7]. The efficacy of artemisinin derivatives
has prompted the use of the original plant, Artemisia
annua, as a herbal tea against malaria [8]. The develop-
ment of traditional herbal medicines for malaria, bio-
screening and modern drug development are not
mutually exclusive.
Patients use TM for many reasons: They may be in a
remote area where modern medicine is not available
when they need it. They may belong to communities
whose habits and treatment-seeking behaviour resorts to
TM as the first choice. They may prefer TM, believing,
for example, that they produce fewer side effects or cures
them more effectively. They may have experienced a fail-
ure with a modern treatment and want to try TM. They
may want to avoid modern health facilities because they
perceive them as expensive, unfriendly, dangerous or rid-
den with corruption. Patients may also avoid modern
drugs sold on the market because they are aware of the
fact that many of them are counterfeit or ‘fake’ drugs .
Some civilizations, e.g. in China and in India, still
practice ancient traditional medicines. Ancient use of
plant medicine has evolved into ‘new’ practices such as
naturopathy, homeopathy, aromatherapy and modern
herbal medicine [10], although many such practices
have not been formally validated.
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Ethnomedical studies provide information on the use,
preferences and ecological viability of plants. For exam-
ple, 16 plants against malaria were found in the commu-
nities living around the Sango Bay Forest Reserve in
southern Uganda [11]. Hallea rubrostipulata, Warburgia
ugandensis and Syzygium guineense were the most
important forest tree species used to treat malaria in the
community. Such studies cannot, however, tell us any-
thing about the effectiveness of these plants. For that,
clinical studies are necessary.
The term “validated”, in clinical practice and health
policy, means that there is enough evidence in clinical
studies to ensure safety and effectiveness (i.e. “evidence-
based medicine”). Is there anything like “evidence-based
TM”? Many physicians are unaware that clinical
research has already been conducted and published on
TM. Although the vast majority of published material
on TM is laboratory research (e.g. phytochemistry or
animal studies), there is also today some clinical evi-
dence of effectiveness in this domain [12].
Once a TM has been validated, it could be tested –
and in case of good results officially recommended – as
an alternative to modern treatments when the latter are
lacking, e.g. when supply is interrupted for logistic rea-
sons. Since very few clinical trials on safety and efficacy
of traditional anti-malarials have been conducted
[12,13], the therapeutic potential of TM may well have
been underestimated. So far safety and effectiveness of
some TMs have been observed, paving the way to better
collaboration between modern and traditional medical
systems. In addition, health system research has uncov-
ered interesting facts about TM, e.g. that TM practi-
tioners are not responsible for late seeking modern
treatment, at least in some settings [14].
TMs appear today a largely untapped health and eco-
nomical resource, with potential importance at both the
individual and population levels [15].
Herbal compounds provided important leads for
modern anti-malarials: quinine and artemisinin
Among the earliest written records of anti-malarial
treatments are a series of Babylonian clay tablets from
about 2600 B.C [10]. Amongst the approximately 1,000
plant-derived substances cited for various ailments were
oils of Cedrus species (cedar) and Cypressus sempevirens
(cypress), Glycyrrhizza glabra (licorice), Camphora spe-
cies (myrrh), and Papaver somniferum (poppy). All these
plants are still used today for the treatment of ailments
ranging from coughs and colds to parasitic infections
and inflammations [16].
Malaria was a scourge in much of Europe until about
three centuries ago. After the Spanish and Portuguese
colonization of South America, the use of the bark of
the Cinchona tree to treat malaria was introduced in
Europe, leading to the discovery of quinine, at the
beginning of the 19th century [17]; it remains the oldest
anti-plasmodial drug still in clinical use. Quinine has
perhaps saved more lives than any other drug known in
history [4,5]. It has also provided a lead template to che-
mists who successfully synthesized aminoquinoline-
based anti-plasmodial analogs, such as chloroquine,
amodiaquine, primaquine and mefloquine, all of which
considerably improved the treatment of malaria.
Pre-modern China is also a source of information
about the early medicinal uses of plants . The Chinese
traditional herbal remedy Qinghao (an Artemisia) has
long been used in China for the treatment of intermit-
tent fevers. It was first noted in a document found in a
tomb dating from 168 B.C., while the first recipe against
intermittent fevers in their acute phase was made by Ge
Hong in the fourth century AD. In 1596, Li Shizen
introduced Ge Hong’s recipe into the materia medica
literature [18-22].
The emergence of chloroquine-resistant P. falciparum
malaria in southeast Asia in the 1960s caught the atten-
tion of the Chinese government [23]. A National Steer-
ing Committee on Antimalaria Research was established
in 1967 and an anti-malarial drug discovery pro-
gramme – encouraged by a war-time request from
North Vietnam – was set up in 1969. As part of the
programme, Chinese scientists examined ancient medi-
cal texts and were drawn to qinghao by Ge Hong’s com-
ments [24]. They confirmed the anti-malarial potency of
Artemisia annua in 1971, developed an effective extrac-
tion process, isolated and identified artemisinin as the
active ingredient in 1972 [20,25,22]. Artemisinin, which
is effective in treating chloroquine-resistant cases, is
quite different from the old generation of anti-malarial
drugs because of its peroxide group [19,26]. Attempts to
derivatise artemisinin were done even before its chemi-
cal structure was fully elucidated. Chemists successfully
semi-synthesized anti-plasmodial analogs, such as dihy-
droartemisinin, artemether, arteether, artesunate and
artelinic acid. The derivatives of artemisinin are widely
recommended today [27].
Traditional practitioners recommend referral for
severe cases
A study in Tanzania showed that increasing the colla-
boration between traditional healers and modern health
care providers has improved the management of severe
malaria [14]. Traditional healers form a natural exten-
sion of the formal health service and there is great
potential for improving both their practice and access to
modern medicines through their training and
collaboration.
That is why it could be advisable to start with a colla-
borative research project on the actual effectiveness of
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some local TM practices, and only then discuss limita-
tions of local care and the necessity for referral of a few
cases. TM practitioners in both Tanzania and Ghana
were very cooperative in referring severe cases of
malaria during the recently completed rectal artesunate
trial, when they were made aware that such cases are
treatable and recover well if referred early [28]. Indeed
experience shows that TM practitioners are, at this
point, ready to discuss referral and happy to improve
their competence in this matter.
In most cases, patients actually perform their own
self-referrals, usually in quite an appropriate manner.
They welcome support in decision making from tradi-
tional practitioners. In a study in Mauritania, it appeared
that TM practitioners performed adequate referrals
without any previous training and were able to predict
patient progress as accurately as modern physicians, an
observation that was attributed to their long clinical
experience [29]. They were able to detect those patients
having a high chance of cure with their treatment, and
those with a low chance. For the latter, they asked their
modern colleagues whether they had something to offer.
Joint meetings were organized where modern and TM
practitioners presented their difficult patients and asked
their counterpart whether they had something to offer.
Appropriate referral was facilitated by such trusting
relationships.
Traditional medicine for malaria control
programmes in the future
Today, TM can still inspire new therapeutic ideas. Some
recipes are being locally validated and will be tested as
part of malaria control programmes [30]. In a longer
term perspective, the TM approach described here can
also be used as a “reverse process” of the classical drug
discovery process; it takes advantage of experience gath-
ered during centuries in areas where local remedies are
used. Where numerous traditional recipes exist for the
same ailment, we can discover the one with the best
outcome, which may represent the most promising
treatment concept. Approaching TM with the objective
of having a net positive impact on malaria control activ-
ities is, however, paved with dangers of doing more
harm than good.
A prerequisite is to have a multidisciplinary team with
excellent technical and human competences, led by a
health professional with experience and rigor in clinical
research, excellent communication skills and demon-
strating a relativist perspective of various medical
knowledge, allowing for a positive and critical view on
all medicines.
A project of TM for malaria control programme could
be organized along the following lines, this suggestion
being based on field experience:
Step 1: Recognize TM as a (sometimes) valuable
health resource
To start with, members of a team working on TM for
malaria control should be aware of the literature and
realize that TM may contribute to malaria control pro-
grammes in several ways:
- TM practitioners can help in referring severe cases
as well as ensuring that pregnant women receive their
intermittent treatment adequately;
- TM may provide validated first-aid treatment for
rapid care in remote areas;
- the use of TM as first-line treatment for semi-
immune population could delay resistance of Plasmo-
dium against the most potent modern anti-malarials;
- new leads for future malaria drugs can be found in
local TM.
A common worry with TM is that doses vary. In addi-
tion to variations in the mode of preparation, the bio-
chemical content of the plant used is not stable across
time and space. The answers to this problem are mani-
fold: for a safe and effective treatment without a precise
and stable dose of active constituents, the therapeutic
range of the selected preparation must be large enough
to allow for wide dose variations, so that the TM retains
enough clinical effect without excessive toxicity. It may
also be possible to find the active constituents for qual-
ity control, a research programme in itself.
- Traditional healers themselves, if reliable and cred-
ible, can be a valuable human resource. The ratio of
population per healer is much smaller than the ratio of
population per nurse or doctor in many areas. Yet the
healers are often overlooked in statistics on human
resources. Cuba is an excellent example of integrated
traditional and modern medicine in the health care sys-
tem with mutual benefits [31].
- The issue of “counterfeit” drugs can be a reason why
TM is preferred, but counterfeit TM does exist as well.
Therefore, a form of quality assurance must be put in place
(e.g. ensuring that the plant is harvested properly and not
confused with others) and work synergistically with exist-
ing quality assurance mechanisms for modern medicine.
- Traditional medicines do convey a potential for eco-
nomic development and poverty reduction through the
involvement of other sectors like agriculture, marine
resources and forestry. Developing large-scale commer-
cial cultivation of medicinal plants and algae or fungi
may provide income to communities and preserve tradi-
tional medicinal knowledge and biodiversity.
Step 2: Foster working relationship with those
using TM
- Health practitioners and physicians or nurses use
different tools for a common aim: health. It is, therefore,
no surprise that field experience showed that practitioners
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of different cultures can find a common language when
consulting together [29]. As awareness of the similarities
between them grows, they can create a good working rela-
tionship, even when their diagnostic and therapeutic tools
differ widely.
- Both TM and modern practitioners can improve
their knowledge. For example traditional practitioners
could receive standard training in anatomy, physiology
and clinical medicine while modern health practitioners
receive training to appreciate the value and potential of
TM. This would improve their understanding of each
other and their ability to collaborate adequately.
- TM practitioners are usually included in the follow-
ing research question: “Among all the different local
treatments for a given ailment, which is the most effec-
tive?” When TM is practiced to some degree in every
family, which is usual, the entire community is con-
cerned with a research project aiming at answering a
question of practical interest locally.
Step 3: Search for safe and effective local TM
- In the case of Artemisia annua, the question has been
asked: why not use the plant itself? The hypothesis was
that it could prevent drug resistance because it is a
“combination therapy” [32]. Phytochemical studies
showed that the content of artemisinin may seem quite
low, even in selected species, but this depends on the
extraction method and several active constituents could
be working in synergy. Results of clinical studies are
promising, however with relatively high recrudescence
rates [33]. Some NGOs have started to encourage local
cultivation of A. annua[8], that grows easily in humid
climates, but not well in dry areas. Another anti-malarial
plant, validated in clinical studies, is Argemone mexicana
[30]; since it grows precisely in the pan-tropical dry belt
(Sahel-type climates), the two plants may become an
example of complementary solutions, geographically
speaking, if further studies confirm their potential in
malaria control.
- After preliminary studies for selection of the best can-
didate, there is a methodological dilemma: designing a
randomized controlled trial (RCT) in standard experimen-
tal conditions or studying the “real world” situation (or at
least ‘as real as possible’). A standard RCT provides sound
information on treatment effects, but is usually designed
with inclusion criteria that are far removed from the actual
indications for malaria treatment in real clinical situations.
As a result, external validity may be low. If the goal is to
gain a reasonable estimate of the effects of a TM recipe if
it is to be recommended for use in home-based or dispen-
sary-based management of malaria, then it will be more
appropriate to choose a study design that compares two
strategies for the management of presumed uncomplicated
malaria on site: TM as first-line with modern treatment
(e.g. ACT) as second-line, versus modern treatment as
first-line. The main endpoint could be incidence of severe
malaria, as a predictor of malaria mortality - or the latter
directly if sample size makes it possible.
- TM testing with patients is made easier than with
modern drugs, because a good documentation of tradi-
tional use alleviates the constitution of the file, provided
that the study is conducted with the TM recipe pre-
pared and applied according to the local traditional use
[35]. This is also specified in the WHO document
“Guidelines for Clinical Study of Traditional Medicines
in the WHO African Region” [36]. Legal requirements,
of course, vary from country to country.
Step 4: Spread results for clinical
recommendations
Results of clinical studies of TM can be important for
different groups:
- For the general public, evidence-based information
will help patients and family make better treatment
choices. For example, they may know better if a certain
TM is a good alternative to modern treatment in some
occasions or if it should be avoided.
- For health administrations, the challenge is to have a
constructive collaboration between traditional and mod-
ern health systems. Activities can be:
◦ Quality control of TM recipes and preparations sold
in the country [37]
◦ Assessment of TM practitioners, certification
◦ Support for clinical research and official validation of
safe and effective TM
◦ Support for drug discovery based on local recipes,
through phytochemistry, in vitro and in vivo studies,
patenting and licensing for drug development
◦ Production of TM of officially controlled quality
◦ Pharmacovigilance on TM products
- For health professionals and academics, in an era of
pluralistic medicine, conventional (academic) medical
centres need to offer basic knowledge on TM and other
“alternative and complementary medicines” (CAM) for
future health professionals, in order to allow then to
inform patients properly on potential usages, dangers
and interactions of TM/CAM. Acting at this level may
well be the intervention with the longest-lasting effect in
terms of spreading more rational views on TM. Until
recently, most medical schools tended to teach only one
type of medicine. For example in India, there were wes-
tern, Ayurvedic, or Unani medical schools. In many
developing countries, there were only western-style
medical schools. Today, there is a growing tendency to
integrate teaching on TM into medical courses, focusing
on clinical research results and the way to rapidly find
such information in available databases. Teaching and
research on TM/CAM in medical school can improve
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the relationship between academic and other practi-
tioners. Universities also have a growing number of doc-
toral students who choose to conduct their master or
doctoral thesis research on TM. These doctoral students
play a very important role in the production of scientific
knowledge on TM.
Step 5: Make TM part of the public health system
If research results on TM are taken seriously, they should
lead to health policy changes, at least as pilot interven-
tions in the field. Such pilot interventions may show
whether a careful integration of TM in health systems
where it was not taken into account will have an impact
on health indicators (Figure 1). In the case of malaria, a
national health policy could introduce, at the district
level, recommendations for using a validated TM treat-
ment as first-line treatment for uncomplicated malaria.
Could wide use of validated TM be a way to delay resis-
tance to modern anti-malarials? A classic way of delaying
drug resistance is to use an alternative when possible. While
resistance to amodiaquine and sulphadoxine-pyrimethamine
is already widespread [38,39], there is also some evidence of
resistance to lumefantrine [40]. Resistance will continue to
spread if last-generation anti-malarials are universally used.
Some patients, however, may not absolutely need them,
because they are semi-immune. In a longitudinal study in
Senegal, clinical outcomes were not worse when old treat-
ments with some parasite resistance were used. Even though
resistance to chloroquine (CQ) rapidly increased from 1992
to 2001, no change in CQ prescription was observed until
the early 2000s, and this was related to the absence of an
obvious decrease in clinical CQ effectiveness [41].
Step 6: TM potential for lead chemical
compounds and drug development
Although this is a logical component of this section, it
will not be covered here, because it has been discussed
extensively in other articles of this supplement.
One point, however, must be stressed: determination of
active compounds has a first, immediate utility in the pro-
cess described above, it provides the basis for quality con-
trol methods. For example, Eritrean public health
professionals sent samples of Argemone mexicana col-
lected near Asmara in order to know if their plant had an
active compounds profile comparable to Malian batches,
and thus could be tried as a locally-produced anti-malarial.
Finally the involvement of other sectors in determin-
ing the economical value of TM and fostering commer-
cial production of TM products will not only create
wealth and reduce poverty, but will also protect biodi-
versity for future generations.
Conclusion
The WHO Regional Committee for Africa strategy for
promoting TM includes the development of local pro-
duction and conservation of medicinal plants, legislation
of TM practice and its integration into conventional
health services.
Despite extensive investments in malaria control,
research and elimination programmes, the disease has
• Preparation: 
– Reinforce disease surveillance system and/or prepare ad hoc studies
– Choose TM to be involved (already clinically validated) and design 
messages to be spread
– Check quality and local availability of validated TM
• Intervention:
– Spread the message on recommended use of TM (« intervention » 
area)
– Reinforce preventive measures and train for appropriate referral
(intervention and control areas)
– Collect data (baselines and with/without intervention) 
• Valorisation: 
– Presentation to health authorities, as scientific publication as well as 
back to the population. 
– Advocacy of health policies in line with research results
Figure 1 Suggested design of a pilot public health malaria control programme involving traditional medicine.
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remained a major public health problem in sub-Saharan
Africa and in many other places. Implementing rational
use of traditional medicine against malaria through
community-based participatory approaches is feasible
and may well help curb the toll of the disease in ende-
mic areas. There is an urgent need for major research
investments in TM clinical and public health to further
develop appropriate solutions for mass application.
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